Covidien (NYSE:COV) subsidiary ev3 wants the Delaware Supreme Court to grant a new trial in a lawsuit over $175 million ev3 allegedly owes its own Appriva Medical acquisition.
Covidien (NYSE:COV) is on the hook for a $175 million milestone owed by subsidiary ev3 Inc. to a company it acquired 11 years ago, plus another possible $100 million in interest, after a Delaware jury’s decision last May.
